Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FKMNtz4baL_FOlu4M-yVTQt0C73E.uncropped.jpg&w=3840&q=75)
Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- ChecktodayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0 and now includes 3 locations, replacing the previous version v2.9.7.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value 'Results First Posted Last Update Posted Revision: v2.9.3' has been updated to 'Results First Posted Last Update Posted Revision: v2.9.5', indicating a revision in the study record details on the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value 2023-07-27 for Overall response rate, Disease control rate, Duration of response, 1 year Overall survival, Progression free survival, Change from baseline in tumor-immune microenvironment, T-cell response, and Immune Infiltrate has been updated to reflect detailed assessments and definitions based on RECIST v1.1 criteria. The revision v2.9.1 has recently changed to 2024-06-25 for Results Posted.SummaryDifference24%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Genetic and Rare Diseases Information Center resources: Stomach Cancer FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Telomelysin (OBP-301) All patients will receive Telomelysin (OBP-301) at 2x10^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks.' This change represents an update in the information provided on the webpage regarding the study details and treatment protocol for the Phase 2 study of Telomelysin (OBP-301) in combination with Pembrolizumab in Esophagogastric Adenocarcinoma.SummaryDifference25%
Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.